AROVELLA THERAPEUTICS

Research AROVELLA THERAPEUTICS (E4NA) on Bullrun: market cap EUR 51.05M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerE4NA
• ExchangeF
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 51.05M
• Financial periodFY2025
• RevenueEUR 136.00K
• Revenue growth700.0%
• Net income-EUR 7.51M
• Free cash flow-EUR 7.34M
• Gross margin100.0%

Valuation Snapshot

latest market cap is EUR 51.05M.

About AROVELLA THERAPEUTICS

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors.

Frequently asked questions

What is AROVELLA THERAPEUTICS's market cap?

AROVELLA THERAPEUTICS's market capitalization is EUR 51.05M.

What does AROVELLA THERAPEUTICS do?

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally.